All posts

Imperus Technologies is hugely undervalued, says Cantor Fitzgerald Canada

Imperus Technologies CEO James Lanthier in Toronto November 17, 2015.

Guidance that was above expectations is more proof that Imperus Technologies (Imperus Technologies Stock Quote, Chart, News: TSXV:LAB) is undervalued, says Cantor Fitzgerald Canada analyst Ralph Garcea.

In a press release issued yesterday, Imperus said it expects to report revenue of approximately $8.3-million and adjusted EBITDA of approximately $2.7-million for the three months ended Dec. 31, 2015.

“We are pleased with our fourth quarter results, which show the enduring and growing profitability of our businesses,” said CEO James Lanthier. “We are even more excited about Imperus’s future and the operational progress we have been making in realizing the benefits of bringing Akamon and Diwip together.”

Garcea believes Imperus will have enough cash on hand to service its debt, and says he sees revenue synergies from the company’s acquisitions.

“With the completion of the Akamon acquisition, LAB will focus on synergies between Diwip and Akamon which include applying Akamon’s leading CRM and player management methodologies to the Diwip player base,” he says. “We expect multiple cross selling opportunities to be created through a vastly expanded base of players and game library.

In a research update to clients Thursday, Garcea maintained his “Buy (Speculative)” recommendation and one-year target price of $0.50 on Imperus Technologies, implying a return of 456 per cent at the time of publication.

More Cantech Analysts

Tagged with: lab
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Cannara Biotech is a buy, Research Capital says

Research Capital analyst Greg McLeish said in a July 29 update that Cannara Biotech (Cannara Biotech Stock Quote, Chart, News,… [Read More]

12 hours ago

Ahead of Q2 results, is Tantalus Systems a buy?

Beacon Securities analyst Gabriel Leung noted in a July 30 report that Tantalus Systems (Tantalus Systems Holding Stock Quote, Chart,… [Read More]

12 hours ago

Sanuwave Health is a buy, Roth Capital says

Roth Capital Markets is initiating coverage of Sanuwave Health (Sanuwave Health Stock Quote, Chart, News, Analysts, Financials NASDAQ:SNWV) with a… [Read More]

13 hours ago

Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in… [Read More]

13 hours ago

Nextracker wins price target raise at Roth

Roth Capital Markets analyst Philip Shen said in a July 28 earnings preview that Nextracker (Nextracker Stock Quote, Chart, News,… [Read More]

13 hours ago

Telus is my top telecom stock, Brian Madden says

Brian Madden, Chief Investment Officer at First Avenue Investment Counsel, said on BNN Bloomberg’s Market Call on July 25 that… [Read More]

1 day ago